Serum/Plasma microRNAs are promising disease biomarkers
- Plug in important regulatory role in many diseases, including cancers
- Integrates biology from both organs including vascular and immune system
- MicroRNA signature
- Readily obtainable from samples in all stages of disease
- Large historical collections exist for discovery
- microRNAs are present in serum but not leukocytes
- Plasma microRNAs are stable under standardized sampling and storage conditions

Blood plasma contains small amount of RNA

Figure 1. Clinical Source of biomarker – 10 mL blood collection.

A universal method for elimination of hemolyzed samples purified with carrier RNA.

Figure 2. Effect of carrier RNA.

- QC plasma for haemoglobin content
- Use carrier RNA during purification
- Avoid the use of heparin collection tubes

Our solutions
- Serum/plasma contains low amounts of nucleic acid
- Nucleic acids present in different blood fractions from a 10 ml blood sample.

Figure 3. Superior sensitivity and linearity of the LNA™-enhanced miRNA RT-qPCR Platform.

Serum/Plasma microRNAs are promising disease biomarkers

- Plug in important regulatory role in many diseases, including cancers
- Integrates biology from both organs including vascular and immune system
- MicroRNA signature
- Readily obtainable from samples in all stages of disease
- Large historical collections exist for discovery
- microRNAs are present in serum but not leukocytes
- Plasma microRNAs are stable under standardized sampling and storage conditions

Blood plasma contains small amount of RNA

Figure 1. Clinical Source of biomarker – 10 mL blood collection.

A universal method for elimination of hemolyzed samples purified with carrier RNA.

Figure 2. Effect of carrier RNA.

- QC plasma for haemoglobin content
- Use carrier RNA during purification
- Avoid the use of heparin collection tubes

Our solutions
- Serum/plasma contains low amounts of nucleic acid
- Nucleic acids present in different blood fractions from a 10 ml blood sample.

Figure 3. Superior sensitivity and linearity of the LNA™-enhanced miRNA RT-qPCR Platform.

Serum/Plasma microRNAs are promising disease biomarkers

- Plug in important regulatory role in many diseases, including cancers
- Integrates biology from both organs including vascular and immune system
- MicroRNA signature
- Readily obtainable from samples in all stages of disease
- Large historical collections exist for discovery
- microRNAs are present in serum but not leukocytes
- Plasma microRNAs are stable under standardized sampling and storage conditions

Blood plasma contains small amount of RNA

Figure 1. Clinical Source of biomarker – 10 mL blood collection.

A universal method for elimination of hemolyzed samples purified with carrier RNA.

Figure 2. Effect of carrier RNA.

- QC plasma for haemoglobin content
- Use carrier RNA during purification
- Avoid the use of heparin collection tubes

Our solutions
- Serum/plasma contains low amounts of nucleic acid
- Nucleic acids present in different blood fractions from a 10 ml blood sample.

Figure 3. Superior sensitivity and linearity of the LNA™-enhanced miRNA RT-qPCR Platform.